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ABSTRACT During heme deficiency in reticulocyte ly-
sates, the heme-regulated protein synthesis inhibitor, HRI,
phosphorylates the a subunit of eukaryotic initiation factor 2
(eIF-2) and thus inhibits protein synthesis. Two factors, eIF-2
and a reticulocyte-lysate supernatant factor that we term RF,
reverse this inhibition. We now report the following. (i) An
active eIF-2 preparation contained, in addition to the three
subunits (a, (3, and y), a 67-kDa polypeptide. Pretreatment of
eIF-2 with polyclonal antibodies against either isolated a
subunit or 67-kDa polypeptide almost completely inhibited the
reversal activity. Upon further fractionation, three-subunit
eIF-2 and the 67-kDa polypeptide were resolved. Neither the
three-subunit eIF-2 nor the 67-kDa polypeptide alone was
active in protein synthesis inhibition reversal. The activity was,
however, restored by combining both the three-subunit eIF-2
and the 67-kDa polypeptide. (ii) Active RF preparations
contained eIF-2 a (unphosphorylated) and (3 subunits and the
67-kDa polypeptide. As with eIF-2, prior treatment of the RF
preparation with antibodies to either the a subunit or the
67-kDa polypeptide almost completely inhibited the reversal
activity. The RF preparation devoid of eIF-2 y subunit did not
form ternary complex (Met-tRNA;MeteIF-2 GTP). The eIF-2 y
subunit in the free form was isolated, and addition of this
isolated y subunit to RF promoted significant ternary-complex
formation. (iii) Purified HRI efficiently phosphorylated the a
subunit in the three subunit eIF-2. However, the extent of such
phosphorylation was significantly reduced when eIF-2 contain-
ing the 67-kDa polypeptide was used. The 67-kDa polypeptide
apparently protected eIF-2 a subunit from HRI-catalyzed
phosphorylation but did not inhibit HRI activity. Based on
these results, we suggest that the protein synthesis inhibition
reversal activity in both eIF-2 and RF is due to the same
components-namely, eIF-2 a subunit and the 67-kDa poly-
peptide. The 67-kDa polypeptide protects eIF-2 a subunit from
HRI-catalyzed phosphorylation and may also be a necessary
component of the functioning eIF-2 molecule.
In heme-deficient reticulocyte lysate, the heme-regulated
protein synthesis inhibitor, HRI, is activated and shuts off
protein synthesis. HRI phosphorylates the a subunit of
eukaryotic peptide-chain-initiation factor 2 (eIF-2). The bulk
of reticulocyte eIF-2 is isolated as eIF-2-GDP. Upon phos-
phorylation, eIF-2[a(P)]-GDP forms an abortive complex
with another peptide-chain-initiation factor, GEF (guanine
nucleotide exchange factor). GEF is presumably present in
limiting amounts inside the cell, and protein synthesis is
inhibited as 30%o of the eIF-2 molecules become phosphoryl-
ated and bind to available GEF (for review, see refs. 1-5).
Several laboratories have reported that addition of exog-
enous eIF-2 (6-9) or the cell supernatant factor preparation
enriched in GEF activity (10-15) reverses protein synthesis
inhibition in heme-deficient reticulocyte lysate. Ten years
ago, our laboratory reported (17) that although a partially
purified eIF-2 preparation contained significant protein syn-
thesis inhibition reversal activity, this activity was com-
pletely absent from a homogeneous eIF-2 preparation con-
taining the three subunits, a, /3, and y. Our group also
reported (18) that RF, the cell supernatant factor that re-
verses protein synthesis inhibition in heme-deficient reticu-
locyte lysate, also promotes ternary-complex (Met-
tRNAf e' eIF-2.GTP) formation by HRI-phosphorylated eIF-
2. As noted above, this RF preparation is enriched in GEF
activity. More recent work provided evidence (19, 20) that
the protein synthesis inhibition reversal activity of the RF
preparation is not directly related to its GEF activity and is
possibly due to the presence of unphosphorylated eIF-2 a
subunit. It was postulated (19, 20) that RF reverses protein
synthesis inhibition as it donates the unphosphorylated eIF-2
a subunit to eIF-2[a(P)]*GDP and reconstitutes active eIF-2
molecules.
In this paper, we report that both active eIF-2 and RF
preparations contain unphosphorylated eIF-2 a subunit and
a 67-kDa polypeptide and that both these components are
necessary for reversal of protein synthesis inhibition. We
present the results of our studies of the characteristics of the
67-kDa polypeptide and its roles in reversal of protein
synthesis inhibition in heme-deficient reticulocyte lysates.
MATERIALS AND METHODS
The sources of materials and the methods used in these
studies were as described (19-21). eIF-2 activity was purified
by DEAE-cellulose (fraction II), phosphocellulose (fraction
III), and CM-Sephadex (fraction IV) chromatography. The
purification procedures were as described by Das et al. (21)
except that the hydroxylapatite chromatographic step was
omitted. NaDodSO4/PAGE of the fraction IV eIF-2 prepa-
ration consistently gave a 67-kDa polypeptide band in addi-
tion to the three eIF-2 bands (Fig. 1). This fraction IV eIF-2
preparation was used for resolution of the 67-kDa polypep-
tide and of eIF-2 containing three subunits, as well as for
isolation of eIF-2 y subunit.
Glycerol Density Gradient Separation of eIF-2 and the
67-kDa Polypeptide. Fraction IV eIF-2 preparation (2 mg) was
layered on top of a glycerol gradient (10-30%, vol/vol)
containing 0.1 M KCI in buffer B (20 mM Tris HCl, pH 7.8/5
mM 2-mercaptoethanol/50 ,uM EDTA/10% glycerol). The
gradients were centrifuged at 45,000 rpm for 26 hr in a
Abbreviations: eIF-2, eukaryotic peptide-chain-initiation factor 2,
which forms Met-tRNAIet'eIF-2.GTP (ternary complex); eIF-
2[a(P)], eIF-2 with phosphorylated a subunit; GEF, guanine nucle-
otide exchange factor; RF, reticulocyte-lysate supernatant factor
that reverses protein synthesis inhibition in heme-deficient reticulo-
cyte lysate; HRI, heme-regulated protein synthesis inhibitor (eIF-2
kinase); dsI, double-stranded-RNA-activated protein synthesis in-
hibitor (eIF-2 kinase).
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FIG. 1. NaDodSO4/PAGE of fraction IV eIF-2 (8 ,ug; lane 1),
fraction V eIF-2 (6.5 ,ug; lane 2), isolated 67-kDa polypeptide (2 ,ug;
lane 3), and isolated eIF-2 y subunit (2.5 ILg; lane 4). Samples were
analyzed in a 15% polyacrylamide/0.09%o NN'-methylenebisacryl-
amide gel in 0.025 M Tris/0.192 M glycine/0.1% NaDodSO4 (pH
8.3).
Beckman SW 50.1 rotor. The gradients were then fraction-
ated with an ISCO density gradient fractionator and 0.3-ml
fractions were collected from the top. Fractions were ana-
lyzed by NaDodSO4/15% PAGE. Early fractions containing
the 67-kDa polypeptide were pooled, immediately concen-
trated by dry Sephadex G-200 (Pharmacia), and then dialyzed
against buffer B containing 0.1 M KCL. The dialyzed solution
was stored frozen in liquid N2. The late fractions containing
eIF-2 activity were pooled, concentrated by dry Sephadex,
dialyzed against buffer B containing 0.1 M KCI (fraction V),
and stored frozen in liquid N2.
Purification of y Subunit. Fraction IV eIF-2 preparation
was dialyzed against phosphate buffer (20 mM potassium
phosphate, pH 7.6/10 mM 2-mercaptoethanol/50 ,uM
EDTA/10% glycerol) and then loaded onto a hydroxylapatite
column that had been equilibrated with the same buffer. The
column was washed with the same buffer and proteins were
eluted as follows. Free y subunit was eluted with 0.2 M
potassium phosphate (pH 7.6), and eIF-2 containing three
subunits (a, 1, and y) and devoid of the 67-kDa polypeptide
was eluted with a potassium phosphate gradient (0.2-0.5 M,
pH 7.6). The fractions were concentrated by Sephadex,
dialyzed against buffer B containing 0.1 M KCI, and stored
frozen in liquid N2-
RF (fraction VI) was purified according to the procedure of
Grace et al. (20). As reported (20), RF is a high molecular
weight protein complex and contains GEF activity.
Preparation of Polydonal Antibodies Against Isolated eIF-2
Subunits and the 67-kDa Polypeptide. Fraction IV eIF-2
preparation was subjected to NaDodSO4/15% PAGE. After
brief (5 min) staining with Coomassie blue R-250, the gel was
thoroughly destained with 25% methanol/10o acetic acid.
Stained bands corresponding to the a, 1, and y subunits and
the 67-kDa polypeptide were excised with a razor blade and
electrophoretically eluted in 100 mM Tris/50 mM Tricine
buffer (22). Each electroeluted protein (25 ,ug) was emulsified
with an equal volume of Freund's complete adjuvant and
injected into the peritoneal cavity of a mouse. After 15 days,
three booster injections of 25 ,ug of isolated polypeptide in
Freund's incomplete adjuvant were given at 1-week inter-
vals. One week after the last injection, blood was collected by
tail-bleeding and the antibody titer in the serum was tested by
ELISA using a /3-galactosidase conjugate. When antibody
titer in the serum was 1:2500, blood was drawn frequently by
tail-bleeding. The antibodies from immune serum were pu-
rified by use of DEAE Affi-Gel Blue, according to the
procedure supplied by the manufacturer (Bio-Rad immuno-
blot assay kit), and were characterized by NaDodSO4/PAGE
followed by immunoblotting.
RESULTS
Fraction IV eIF-2 preparation consistently showed a 67-kDa
polypeptide in addition to the usual three eIF-2 subunits (Fig.
1, lane 1). Upon further fractionation by glycerol density
gradient centrifugation, eIF-2 containing three subunits (frac-
tion V; lane 2) was resolved from the 67-kDa polypeptide
(lane 3). The eIF-2 y subunit (lane 4) was obtained by
hydroxylapatite chromatography of fraction IV eIF-2. Small
but significant amounts ofeIF-2 y subunit (5-10%6 ofthe input
eIF-2 y subunit) were eluted with 0.2M potassium phosphate
buffer (pH 7.6). eIF-2 containing three subunits (a, 13, and y)
and devoid of the 67-kDa polypeptide was later eluted from
the column with a 0.2-0.5 M potassium phosphate gradient
(pH 7.6). All three eIF-2 preparations (fractions IV and V and
the hydroxylapatite-purified eIF-2 fraction) formed >70% of
the expected stoichiometric amount ofternary complex in the
presence ofexcess Co-eIF-2 (a factor that stimulates ternary-
complex formation; ref. 5) and in the absence of Mg2". The
isolation of free eIF-2 y subunit suggests that this subunit
either was present in slight excess in the fraction IV eIF-2
preparation or was loosely bound to the eIF-2 complex.
Both eIF-2 and the 67-kDa Polypeptide Are Required for
Reversal of Protein Synthesis Inhibition in Heme-Deficient
Reticulocyte Lysate. We tested eIF-2 preparations fractions
IV and V and the isolated 67-kDa polypeptide for the ability
to reverse protein synthesis inhibition. Whereas fraction IV
eIF-2 efficiently reversed protein synthesis inhibition, frac-
tion V eIF-2 was almost completely inactive (Fig. 2A). Also,
the 67-kDa polypeptide alone was almost completely inactive
(Fig. 2C). The reversal activity could be reconstituted,
however, by combining fraction V eIF-2 and the isolated
67-kDa polypeptide, indicating that both three-subunit eIF-2
and the 67-kDa polypeptide are essential for reversal action
(Fig. 2 B and C).
Presence of eIF-2 Subunits and the 67-kDa Polypeptide in
eIF-2 and the RF Preparation. Besides eIF-2, the reticulocyte
-J
U)
2 3 4 5 2 3 4 5 0.3 0.6 0.9 1.2 1.5
FACTOR ADDED (pg) eIF-27ADDED (.tg) 67kDa ADDED (pg)
FIG. 2. Reversal activity of fraction IV eIF-2, fraction V eIF-2,
and 67-kDa polypeptide. Protein synthesis in heme-deficient reticu-
locyte lysate was assayed by the standard procedure (19). [14C]Leu-
cine (specific activity, 160 cpm/pmol) incorporation was determined
in 20-IAl aliquots of the reaction mixture. Mixtures contained (in a
total volume of25 ,Al) various amounts offraction IV eIF-2 orfraction
V eIF-2 (A), various amounts of fraction V eIF-2 with or without a
fixed amount (1.2 jg) of67-kDa polypeptide (B), or various amounts
of 67-kDa polypeptide with or without a fixed amount (4.8 ,ug) of
fraction V eIF-2 (C).
Biochemistry: Datta et al.







cell supernatant factor preparation RF (18-20) actively re-
verses protein synthesis inhibition in heme-deficient reticu-
locyte lysates. To compare the characteristics of the com-
ponents in both eIF-2 and RF preparations that are respon-
sible for reversal activity, we analyzed both active eIF-2
(fraction IV) and RF preparations for the presence of eIF-2
subunits and the 67-kDa polypeptide (Fig. 3). For this
experiment, we used polyclonal antibodies against individu-
ally isolated eIF-2 a, /3, and y subunits and the 67-kDa
polypeptide in an immunoblotting assay. As reported (20),
the RF preparation contains several polypeptides besides the
eIF-2 a subunit. Fig. 3 shows that the polyclonal antibodies
reacted specifically with the corresponding polypeptides,
although the antibodies against 13 subunit showed some
crossreactivity. The results show that the active RF prepa-
ration contains eIF-2 a and P subunits and the 67-kDa
polypeptide but is devoid of eIF-2 'y subunit. Complete
absence of the eIF-2 y subunits in the active RF preparation
explains the lack of ternary-complex-forming activity of RF.
Identification of the Polypeptide Components in Both eIF-2
and RF Preparations Responsible for Reversal of Protein
Synthesis Inhibition. To determine which polypeptide com-
ponents in eIF-2 and RF preparations are responsible for the
reversal activity, we pretreated these preparations with
polyclonal antibodies against a, /3, y, and the 67-kDa poly-
peptide for 1 hr at0C and then analyzed the pretreated factor
preparations for reversal of protein synthesis inhibition
(Table 1). Pretreatment of both eIF-2 and RF preparations
with polyclonal antibodies against a subunit and the 67-kDa
polypeptide almost completely inhibited the reversal activity.
Pretreatment with antibodies against eIF-2 y subunit showed
significant inhibition when eIF-2 was used but had negligible
effect when RF, which is devoid of 'y subunit, was used.
Under similar conditions, pretreatment ofeither fraction with
antibodies against the /3 subunit had very little effect. Lack of
Table 1. Effects of antibodies on protein synthesis inhibition




added + Hemin Control (IV) + RF (VI)
None 396 100 340 248
Anti-a 115 109
Anti-P - 303 213
Anti-y 176 216
Anti-67-kDa 127 97
Protein synthesis in heme-supplemented and heme-deficient re-
ticulocyte lysate was assayed by the standard procedure (19).[14C]Leucine incorporation was determined in 20-,ul aliquots of the
reaction mixture. Where indicated, 4.5 ,ug of fraction IV eIF-2, 7.5
,ug of fraction VI RF, and 10 ,ug of Affi-Gel Blue-purified antibodies
against specific polypeptides were added.
8
FIG. 3. Immunoblot analysis of frac-
tion IV eIF-2 and fraction VI RF. The
proteins were subjected to NaDod-
S04/PAGE and electrophoretic trans-
fer to nitrocellulose sheets. The nitro-
cellulose sheets were then treated as
described in the Bio-Rad immunoblot
kit. Lanes 1-4, fraction IV eIF-2 (5 ,g
per lane); lanes 5-8, fraction VI RF (30
,ug per lane). Nitrocellulose strips were
incubated with antibodies to a subunit
(lanes 1 and 5), to /8 subunit (lanes 2
and 6), to 'y subunit (lanes 3 and 7), or
to 67-kDa polypeptide (lanes 4 and 8).
inhibition by eIF-2 /3-subunit antibodies is not surprising, as
previous studies have indicated that the /3 subunit is not
essential for eIF-2 activity (21, 23, 24). However, in this
experiment,B-subunit antibodies served as a control in place
of normal or preimmune mouse IgG.
These results suggest that both eIF-2 and RF preparations
require eIF-2 a subunit as well as the 67-kDa polypeptide for
reversal activity.
Reconstitution of eIF-2 from its Subunits. As noted above,
the RF preparation, devoid of eIF-2 Sy subunit, does not form
a ternary complex. We tested the possibility that the addition
of free eIF-2 y subunit to RF would restore the ternary-
complex-forming activity (Fig. 4). Neither eIF-2 y subunit
alone nor the RF preparation formed a ternary complex.
However, when eIF-2 y subunit was added to the RF
preparation, significant ternary-complex formation was ob-
Y-SUBUNIT ADDED (pLg)
FIG. 4. Reconstitution of ternary complex formation (Met-
tRNAMMt bound in pmol) by fraction VI RF with increasing concen-
tration of added eIF-2 y subunit. Reaction mixtures contained (in a
total volume of 0.075 ml) 20 mM Tris HCl (pH 7.5), 100 mM KCI, 10
,ug of bovine serum albumin, 2 mM dithiothreitol, 7.5 jig of fraction
VI RF, 15 pmol of [35SIMet-tRNAmet (10,000 cpm/pmol), and vari-
ous concentrations of eIF-2 y subunit.
3326 Biochemistry: Datta et al.
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FIG. 5. Phosphorylation of eIF-2 a subunit (38 kDa) with ATP
and HRI in the presence or absence of 67-kDa polypeptide. The
reaction conditions were as described (19). The reaction mixtures
were incubated at 370C for 10 min, except for the samples in lanes 6
and 7 (in A), which were incubated at 37TC for 20 min. Reactions were
terminated by adding an equal volume of 2% NaDodSO4/50 mM
2-mercaptoethanol/50 mM Tris-HCl, pH 7.0/50%o glycerol/0.2%
bromophenol blue. Samples were heated at 100TC for 3 min,
subjected to NaDodSO4/15% PAGE, and autoradiographed on
Kodak X-Omat AR-5 film for 12 hr with DuPont intensifying screen.
(A) Lanes 1 and 2, fraction V eIF-2 (3.5 and 7.0 pmol, respectively);
lanes 3 and 4, fraction IV eIF-2 (3.5 and 7.0 pmol); lane 5, fraction
V eIF-2 (7.0 pmol) plus 67-kDa polypeptide (1 ,ug) added at zero time
of incubation; lane 6, fraction V eIF-2 (7.0 pmol) plus 67-kDa
polypeptide (1 ug) added after 10 min of incubation and then
incubated at 37TC for another 10 min; lane 7, fraction V eIF-2 (7.0
pmol) incubated at 37TC for 20 min. (B) Lanes 1-4, same as inA; lanes
5 and 6, fraction V eIF-2 plus fraction IV eIF-2 (3.5 pmol of each and
7.0 pmol of each, respectively).
served and the complex formation increased with the amount
of y subunit added.
The 67-kDa Polypeptide Inhibits HRI-Catalyzed Phospho-
rylation of eiF-2 a Subunit. HRI efficiently phosphorylated
the a subunit present in fraction V three-subunit eIF-2 (Fig.
SA, lanes 1 and 2) and the extent of such phosphorylation was
significantly lowered when fraction IV eIF-2, containing the
67-kDa polypeptide, was used (lanes 3 and 4). Also, the
phosphorylation of the three-subunit eIF-2 was significantly
inhibited when fraction V was mixed with the isolated 67-kDa
polypeptide (lane 5). This 67-kDa polypeptide does not
contain eIF-2[a(P)J phosphatase activity; addition of the
67-kDa polypeptide after phosphorylation offraction V eIF-2
did not dephosphorylate eIF-2[a(P)] (lane 6). However, such
addition, as expected, prevented further phosphorylation of
the remaining unphosphorylated eIF-2 (lane 6), whereas a
control experiment without added 67-kDa polypeptide
showed continued phosphorylation during the additional
incubation period (lane 7). The 67-kDa polypeptide in fraction
IV eIF-2 protected the eIF-2 a subunit from HRI-catalyzed
phosphorylation but did not inhibit HRI activity; the added
HRI in the reaction mixture did not phosphorylate the a
subunit in fraction IV eIF-2 (Fig. SB, lanes 3 and 4) but
efficiently phosphorylated the a subunit in fraction V eIF-2
when the two eIF-2 preparations were added together (lanes
5 and 6). These results suggest that the 67-kDa polypeptide
protects the eIF-2 a subunit from HRI-catalyzed phospho-
rylation.
DISCUSSION
Data presented in this paper show that eIF-2 and RF, which
have been reported to reverse protein synthesis inhibition in
heme-deficient reticulocyte lysates (6-20), possibly reverse
inhibition by the same mechanism; in both cases the active
components include the eIF-2 a subunit and the 67-kDa
polypeptide. The active components in eIF-2 preparations
include the 67-kDa polypeptide in addition to the usual three
subunits contained in eIF-2. The active RF preparation con-
tains the same 67-kDa polypeptide and the eIF-2 a and (,
subunits. In the presence of the 67-kDa polypeptide, the eIF-2
a and ,8 subunits in RFjoin with added y subunit to form active
eIF-2 molecules competent in ternary-complex formation.
We suggest the following model for regulation of protein
synthesis initiation in reticulocyte lysates containing eIF-2
and the 67-kDa polypeptide. The active components of the
eIF-2 molecules in reticulocyte lysates include the 67-kDa
polypeptide as well as the usual three subunits, a, (3, and y.
The 67-kDa polypeptide is postulated to be present in limiting
amounts. The reticulocytes, therefore, contain varying
amounts of four-subunit eIF-2 (a, (3, , and 67 kDa), three-
subunit eIF-2 (a, 83, and y), and pools of free subunits. The
eIF-2 kinases (HRI, activated in the absence of hemin, and
dsl, activated by double-stranded RNA) phosphorylate the
three-subunit eIF-2 but not the four-subunit eIF-2 (Fig. 5) or
free eIF-2 a subunits (25). Protein synthesis is inhibited as
phosphorylated three-subunit eIF-2 effectively competes
with the four-subunit eIF-2 for some limiting component of
the protein synthesis machinery or as eIF-2[a(P)J]GDP binds
to the available 67-kDa polypeptide and inactivates it. Ad-
dition of excess 67-kDa polypeptide and unphosphorylated
eIF-2 a subunit leads to the formation of excess four-subunit
eIF-2, which can compete effectively with endogenous eIF-
2[a(P)]-GDP to form active ternary complex. Protein synthe-
sis can, therefore, be restored without significant change in
the level of eIF-2 a-subunit phosphorylation. It should be
noted, however, that addition of either the 67-kDa polypep-
tide or three-subunit eIF-2 alone did not reverse protein
synthesis inhibition in heme-deficient reticulocyte lysate
(Fig. 2). Apparently, under the experimental conditions, (i)
the added 67-kDa polypeptide failed to inhibit the limiting
eIF-2 a-subunit phosphorylation necessary for protein syn-
thesis inhibition and (ii) the concentration of unphosphory-
lated eIF-2 a subunit became limiting. It may be that in the
presence of inhibitory, phosphorylated eIF-2 a subunit, the
affinity of the 67-kDa polypeptide for the three-subunit eIF-2
is reduced so that higher concentrations of both 67-kDa
polypeptide and three-subunit eIF-2 are necessary for inter-
action and subsequent formation of four-subunit eIF-2.
Finally, we emphasize that there is now convincing evi-
dence that mammalian cells extensively use eIF-2 a-subunit
phosphorylation to regulate protein synthesis and possibly to
promote preferential translation of different mRNAs (26-29).
However, activation of eIF-2 kinases leading to complete
phosphorylation of eIF-2 a subunit should result in a total
loss of protein synthesis activity of the cells and eventual cell
death. There are, however, mechanisms available whereby
the cells can inactivate or inhibit the eIF-2 kinase(s), prefer-
ably at a certain developmental stage, and thus promote
preferential translation ofmRNAs available at that stage. For
example, Siekierka et al. (27) and Schneider et al. (28)
reported that synthesis of excess double-stranded RNA
inhibits activation of dsI during adenovirus infection of
animal cells. Similarly, Rice and Kerr (29) reported the
synthesis of an inhibitor of dsI during the late phase of
vaccinia virus infection. The characteristics of this inhibitor
of eIF-2 kinase are not known. The results presented here
provide evidence that the 67-kDa polypeptide protects the
eIF-2 a subunit from phosphorylation by eIF-2 kinase. The
levels of this 67-kDa polypeptide at different developmental
stages may thus be a critical factor in regulating protein
synthesis in animal cells and also in promoting preferential
translation of mRNAs.
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